Levetiracetam Mylan

Levetiracetam, the active ingredient in Levetiracetam Mylan, is an antiepileptic presented as an intravenous solution for intravenous use. It is employed to control partial‑onset seizures, generalized tonic‑clonic seizures, and myoclonic seizures in patients who require rapid or continuous seizure management, including those unable to take oral medication.

GNH USA supplies Levetiracetam Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product meets EU regulatory standards and is manufactured under strict quality controls.

Levetiracetam is an antiepileptic medication used to manage seizure disorders. - Partial‑onset seizures: reduces the frequency and severity of focal seizures that start in a localized area of the brain. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes that involve loss of consciousness and bilateral muscle stiffening and rhythmic jerking. - Myoclonic seizures: controls sudden brief muscle jerks, reducing their occurrence and improving daily functioning for patients with this seizure type. - Adjunctive therapy for refractory seizures: used in combination with other antiepileptics when seizures are not controlled by monotherapy.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious. Common Side Effects: - Dizziness: sensation of lightheadedness or unsteadiness that may affect balance. - Fatigue: feeling unusually tired or weak, potentially impacting daily activities. - Nausea: upset stomach with an urge to vomit, often transient. - Headache: mild to moderate head pain that may worsen with activity. - Irritability: mood changes or increased agitation, often observed in some patients. Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing requiring immediate medical attention. - Stevens-Johnson syndrome: serious skin blistering and detachment that can be life‑threatening. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation, necessitating prompt evaluation.

When using levetiracetam, certain precautions should be observed to ensure safe and effective therapy. - Renal function: assess and adjust dose in patients with impaired kidney function. - Psychiatric monitoring: watch for mood changes, depression, or suicidal ideation. - Concomitant CNS depressants: use caution as combined effects may increase sedation. - Pregnancy and lactation: evaluate risks and benefits before prescribing to pregnant or breastfeeding women. - Drug interactions: review all current medications for potential interactions. - Store at ambient temperature: keep the solution below 25°C, protect from light, and store in the original container.

Levetiracetam may interact with other medicines; awareness of major and moderate interactions helps optimize therapy. Major Interactions (Avoid): - Carbamazepine: co‑administration may reduce levetiracetam plasma concentrations, potentially diminishing seizure control efficacy. - Phenobarbital: concurrent use can lower levetiracetam levels, which may compromise therapeutic effectiveness in seizure management. Moderate Interactions (Monitor Closely): - Opioids: additive central nervous system depression may increase sedation and respiratory depression risk. - Fluoroquinolones: may enhance neurotoxic potential of levetiracetam, requiring close neurological monitoring. - Alcohol: combined consumption can intensify dizziness, somnolence, and impair cognitive function. - Antidepressants: may increase the risk of mood alterations or depressive symptoms when used with levetiracetam. - Other antiepileptics: concurrent therapy may have additive anticonvulsant effects, necessitating dose adjustments.